Syncromune™ is uniquely focused on the development of intratumoral immunotherapy approaches for treating solid tumors. We are committed to bringing life-changing treatments to patients with unmet medical needs by fighting cancer in a new way. The company is developing Syncrovax™, a proprietary platform technology that uses a combination multi-medicine intratumoral immunotherapy approach that can deliver systemic responses, including durable complete responses.

There is a significant unmet need for an effective metastatic cancer treatment. Most patients with metastatic solid tumor cancers still do not benefit from systemic immunotherapies and succumb to their cancer. In addition, although the combination of two systemically administered immunotherapies has resulted in improved outcomes in some cancers, its use can be limited by severe toxicities.

An intratumoral combination approach to overcoming metastatic cancer: Syncrovax™. This platform therapy has the potential to offer better outcomes for patients with metastatic solid tumor cancers that have failed available standards of care. We believe there is a robust scientific rationale for the Syncrovax™ therapy and early clinical validation has demonstrated strong positive signals. In addition, intratumoral administration may provide the opportunity to effectively utilize combination immunotherapy to elicit systemic responses with lower toxicities due to a lower dose, higher concentration multi-medicine drug.
Our unique loco-regional approach combines an in situ vaccine with combinations of four immunotherapeutic drug components that attack several immunosuppressive mechanisms of cancer all at once. This administration of multiple drugs would likely be limited by toxicities and targeting if delivered systemically.
Syncromune™ has devised a unique, lower risk approach to developing immunotherapeutics. We develop new molecular entities (NMEs) for intratumoral administration by combining NMEs that are already under development for systemic administration. We exclusively in-license multiple proprietary, clinical stage NMEs. Based on clinical data and scientific rationale, we combine those component NMEs to make fixed-dose multi-medicine proprietary drugs with a plan to build additional layers of IP protection.

2919 E COMMERCIAL BLVD
Suite 200
Fort Lauderdale, Florida 33308
United States
Map It